# Special Issue

# 3D Cell Culture Cancer Models: Development and Applications

## Message from the Guest Editors

Despite the advances in the treatment, cancer is still in the top 10 causes of death worldwide. Therefore, the need of new patient-derived cancer models to improve personalized therapy is critical. Due to their ability to recapitulate the structural and functional aspect of their matched organs, 3D cell culture cancer models have received huge attention from a variety of specialized fields, including cell biology, molecular biology, chemistry, physics, engineering and nanotechnology This Special Issue aims to bring together scientists and physicians to discuss the state-of- the-art in *in vitro* cancer modeling. The goal is to highlight those approaches that will drive future research in the study of 3D cell culture cancer models for personalized drug sensitivity testing or to study the tumor cell physiology. Reviews, articles and protocols that explore advanced materials and methods to generate 3D *in vitro* tumor models that mimic the native heterogeneity and the three-dimensionality of their *in vivo* counterparts are welcome.

## Guest Editors


Dr. Loretta L. del Mercato

CNR-Institute of Nanotechnology, c/o Campus Ecotekne, Via Monteroni, 73100 Lecce, Italy

Dr. Erika Parasido

Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA


## Deadline for manuscript submissions

closed (31 July 2020)


# Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/39505

*Cancers*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

# Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

# About the Journal

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## Author Benefits

**Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)